We are live on
!
Find out more
BA
BlackRock Advisors Portfolio holdings
AUM
$98.8B
1-Year Est. Return
15.8%
This Fund
S&P 500
This Quarter
Est. Return
-7.26%
1 Year Est. Return
+15.8%
3 Year Est. Return
+32.35%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$93.3B
AUM Growth
-$2.89B
(-3%)
Cap. Flow
+$5.74B
Cap. Flow
% of AUM
6.15%
Top 10 Holdings %
Top 10 Hldgs %
15.28%
Holding
3,878
New
163
Increased
1,568
Reduced
1,679
Closed
111
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$423M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$367M |
| 3 |
ExxonMobil
XOM
|
+$337M |
| 4 |
Johnson & Johnson
JNJ
|
+$257M |
| 5 |
Biogen
BIIB
|
+$250M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$195M |
| 2 |
AbbVie
ABBV
|
+$188M |
| 3 |
JPMorgan Chase
JPM
|
+$183M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$176M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$174M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.49% |
| 2 | Financials | 16.75% |
| 3 | Technology | 9.99% |
| 4 | Industrials | 8.32% |
| 5 | Energy | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2626
AngioDynamics
ANGO
$593M
| $229K | ﹤0.01% |
17,394
+140
| +0.8% | +$2.11K |
|
2627
Global Net Lease
GNL
$1.86B
| $229K | ﹤0.01% |
+8,301
| New | +$212K |
|
|
RDUS
2628
DELISTED
Radius Recycling
RDUS
| $229K | ﹤0.01% |
16,907
-171,287
| -91% | -$2.8M |
|
|
FNHC
2629
DELISTED
FedNat Holding Company Common Stock
FNHC
| $229K | ﹤0.01% |
9,554
-378
| -4% | -$8.84K |
|
|
NAVB
2630
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
| $229K | ﹤0.01% |
5,026
-288
| -5% | -$10.9K |
|
2631
Independent Bank Corp
IBCP
$797M
| $228K | ﹤0.01% |
15,430
+2,956
| +24% | +$41.6K |
|
2632
Park Aerospace
PKE
$747M
| $228K | ﹤0.01% |
12,951
-466
| -3% | -$8.24K |
|
|
SHOE
2633
Shoe Station Group
SHOE
$431M
| $228K | ﹤0.01% |
19,196
-160
| -0.8% | -$2.13K |
|
2634
Tonix Pharmaceuticals
TNXP
$158M
| – | – |
0
| – | – |
|
2635
iShares Silver Trust
SLV
$27.6B
| $227K | ﹤0.01% |
16,333
-135
| -0.8% | -$1.92K |
|
|
XCRA
2636
DELISTED
Xcerra Corporation
XCRA
| $227K | ﹤0.01% |
36,086
+90
| +0.3% | +$576 |
|
|
HSII
2637
DELISTED
Heidrick & Struggles
HSII
| $226K | ﹤0.01% |
11,634
-123
| -1% | -$2.65K |
|
|
GNMK
2638
DELISTED
GenMark Diagnostics, Inc
GNMK
| $226K | ﹤0.01% |
28,754
+564
| +2% | +$5.22K |
|
|
GOOD
2639
Gladstone Commercial Corp
GOOD
$627M
| $225K | ﹤0.01% |
15,944
+543
| +4% | +$8.32K |
|
|
TVTY
2640
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $225K | ﹤0.01% |
20,217
-1,404
| -6% | -$17.2K |
|
|
BKMU
2641
DELISTED
Bank Mutual Corp
BKMU
| $225K | ﹤0.01% |
29,314
-2,215
| -7% | -$16.2K |
|
|
REGI
2642
DELISTED
Renewable Energy Group, Inc.
REGI
| $225K | ﹤0.01% |
27,117
+610
| +2% | +$5.78K |
|
|
EPZM
2643
DELISTED
Epizyme, Inc
EPZM
| $224K | ﹤0.01% |
17,435
-349
| -2% | -$7.04K |
|
|
SCNB
2644
DELISTED
Suffolk Bancorp
SCNB
| $223K | ﹤0.01% |
8,158
-247
| -3% | -$6.79K |
|
|
REV
2645
DELISTED
Revlon, Inc.
REV
| $223K | ﹤0.01% |
7,582
-337
| -4% | -$11.5K |
|
2646
Axcelis
ACLS
$3.69B
| $222K | ﹤0.01% |
20,821
+1,936
| +10% | +$23.6K |
|
|
UAM
2647
DELISTED
Universal American Corp
UAM
| $222K | ﹤0.01% |
32,511
+87
| +0.3% | +$705 |
|
|
ORBC
2648
DELISTED
ORBCOMM, Inc.
ORBC
| $222K | ﹤0.01% |
39,739
+630
| +2% | +$3.79K |
|
|
AGEN
2649
Agenus
AGEN
$275M
| $221K | ﹤0.01% |
2,451
-189
| -7% | -$28K |
|
2650
Arrowhead Research
ARWR
$12.1B
| $221K | ﹤0.01% |
38,422
+477
| +1% | +$3K |
|
Similar funds
BIM
BJ
IC
EAM
MFS
CIM
KAM
PFM
BlackRock Advisors's Q3 2015 Portfolio in Review
As of Q3 2015, BlackRock Advisors held 3,878 positions worth $93.3B, down 3% from $96.2B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
BlackRock Advisors deployed $5.74B of net new capital in Q3 2015, opening 163 new positions and adding to 1,568 existing holdings. Its largest new stake was Allergan plc: 186,940 shares worth $176M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 20% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $195M trimmed.
- BlackRock Advisors's largest Q3 2015 buy was Allergan plc: 186,940 shares worth $176M.
- BlackRock Advisors added most to Apple in Q3 2015, an estimated $423M increase.
- BlackRock Advisors's biggest Q3 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $195M.
- BlackRock Advisors fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $108M.
- BlackRock Advisors's ten largest holdings make up 15% of its $93.3B portfolio in Q3 2015.
- BlackRock Advisors opened 163 new positions and closed 111 in Q3 2015.
- BlackRock Advisors's portfolio value fell 3% quarter-over-quarter to $93.3B.
Based on BlackRock Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.